INBX vs UDR · rev $1.3M vs P/E 26, rev $1.71B
Inhibrx Biosciences, Inc. (INBX) versus UDR Inc (UDR) — a side-by-side from cached financials, not a winner call.
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on US.
UDR Inc (UDR) is a reit - residential company listed on NYSE.
Latest reported INBX revenue for 2025-12-31 was $1.3M. Net income was -$140.1M. Revenue was up 550.0% from 2024-12-31 to 2025-12-31. INBX currently screens at market cap $1.28B.
Latest reported UDR revenue for 2025-12-31 was $1.71B. Net income was $377.7M. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. UDR currently screens at market cap $13.95B and trailing P/E 25.6.
INBX currently screens at market cap $1.28B. UDR currently screens at market cap $13.95B and trailing P/E 25.6.
Not investment advice. Open the INBX and UDR stock pages for the full models.
Not investment advice.